Building Your Care Team and First Visit Prep
At a Glance
People with metastatic PitNET, also called pituitary carcinoma, should seek care at a specialized center with a team of relevant specialists. Before the first visit, gather complete brain and spine MRI images, pathology, surgical, radiation, hormone, and medication records.
Because metastatic PitNET (pituitary carcinoma) is exceptionally rare—affecting roughly 0.1% to 0.2% (1 or 2 in 1,000) of people with a pituitary tumor—the most important step in your care is finding a team with specific expertise in this condition [1][2]. General oncology centers may see many cancers, but they rarely encounter a pituitary tumor that has spread [3].
Why a Specialized Center Matters
Experts strongly recommend that you seek care at a specialized center with documented expertise in pituitary and metastatic neuroendocrine tumors [3][4]. These centers provide a multidisciplinary approach, meaning a team of different specialists meets regularly to discuss your case and coordinate your treatment plan [2][5].
While community oncologists can absolutely participate in delivering your coordinated care (especially for chemotherapy administered close to home), the core strategy should be guided by this expert team.
Your core care team should include:
- Neuro-oncologist: A doctor who specializes in using chemotherapy and targeted therapies for tumors of the brain and nervous system [6].
- Specialized Pituitary Neurosurgeon: A surgeon with extensive experience in “skull-base” surgery, specifically for the pituitary region [7][8].
- Endocrinologist: A specialist focusing on the complex hormone systems of the brain [7].
- Radiation Oncologist: A specialist who uses precisely targeted radiation to control tumor growth [7][9].
- Endocrine Pathologist or Neuropathologist: A pathologist with pituitary experience, expert at identifying the specific “lineage” and growth markers of these cells [6][10].
Preparing for Your First Visit
When you visit a specialized center for the first time, or for a second opinion, providing a complete “medical footprint” is essential. The doctors need to see not just the current state of the tumor, but its entire history [11]. Often, imaging and pathology can be sent through secure institutional systems rather than requiring you to carry them personally, but you should confirm this prior to your visit.
Essential Records to Gather
- Imaging: All MRI scans of your brain and spine, including the “raw” images (DICOM files), not just the written reports [12].
- Pathology Materials: Ask the hospital where your surgeries were performed to transfer your glass slides and paraffin blocks. A second-opinion center will want their own experts to look at these under a microscope to confirm the diagnosis [6][10].
- Surgical Reports: The operative notes from every pituitary surgery you have ever had [8].
- Treatment History: If you have had radiation, obtain the “radiation summary,” which includes the exact dose and the area that was treated [9].
- Hormone Panels and Medications: A chronological list of your blood test results for hormones like ACTH, cortisol, and prolactin, plus a complete list of your current endocrine replacement doses, allergies, and prior chemotherapy toxicities [11].
The Multidisciplinary Tumor Board
One of the hallmarks of a top-tier center is the Multidisciplinary Tumor Board. This is a standing meeting where your surgeon, oncologist, endocrinologist, and radiologist sit in a room together to review your scans and pathology [4][13].
This “group think” is vital for metastatic PitNET because the treatment often requires balancing multiple priorities—such as when to use radiation versus chemotherapy, or how to manage severe hormone excess while recovering from surgery [2][14].
Vetting Your Team
Don’t be afraid to ask direct questions about the team’s experience. Ask if they have treated patients with your specific hormone subtype (e.g., ACTH or Prolactin) and if they have experience managing metastasis to distant sites like the liver or bone [15][9]. This helps ensure you are not just a “rare case” to them, but a patient they are prepared to manage with the latest evidence-based protocols [2].
Common questions in this guide
Why is a specialized center important for pituitary carcinoma?
What should I bring to a first visit or second opinion for pituitary carcinoma?
What happens in a pituitary tumor board?
How can I tell whether a team has enough experience with metastatic PitNET?
Which scans can show whether pituitary carcinoma has spread?
How is care coordinated among all of the pituitary carcinoma specialists?
What emergency plan should I ask about after hours?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does this center have a dedicated pituitary multidisciplinary tumor board that includes specialists in neuro-oncology, pituitary neurosurgery, and endocrinology?
- 2.How many cases of metastatic PitNET or aggressive pituitary tumors does your team manage each year?
- 3.Will your own pathology department re-review my original and metastatic slides to confirm the lineage and growth markers (like Ki-67 and transcription factors)?
- 4.Who will be my primary point of contact or 'navigator' to coordinate appointments and communication between all the different specialists on my team?
- 5.How does your team handle emergencies, such as a sudden change in my vision or a suspected adrenal crisis, after hours?
- 6.What specific imaging (such as a spine MRI or a specialized PET scan) do you recommend to fully stage the extent of the tumor's spread?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (15)
- 1
Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review.
Yoo F, Kuan EC, Heaney AP, et al.
Pituitary 2018; (21(3)):290-301 doi:10.1007/s11102-018-0872-8.
PMID: 29404894 - 2
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.
Raverot G, Burman P, McCormack A, et al.
European journal of endocrinology 2018; (178(1)):G1-G24.
PMID: 29046323 - 3
Multimodal therapy in aggressive pituitary tumors.
Iglesias P, Magallón R, Mitjavila M, et al.
Endocrinologia, diabetes y nutricion 2020; (67(7)):469-485 doi:10.1016/j.endinu.2019.08.004.
PMID: 31740190 - 4
Pituitary adenoma…nomen omen?
Giustina A
Endocrine 2021; (74(1)):1-4 doi:10.1007/s12020-021-02785-z.
PMID: 34114192 - 5
Aggressive pituitary tumors and pituitary carcinomas: Definition, management, and overview for clinical practice.
Calvanese F, Jannelli G, Feuvret L, et al.
Neuro-oncology advances 2025; (7(Suppl 1)):i17-i28 doi:10.1093/noajnl/vdae114.
PMID: 40718389 - 6
Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas.
Raverot G, Burman P, Abreu AP, et al.
European journal of endocrinology 2025; (192(6)):R45-R78 doi:10.1093/ejendo/lvaf100.
PMID: 40506054 - 7
Chinese consensus on the diagnosis and treatment of prolactinomas (2025 edition).
Lin S, Chen Z, Ji L, et al.
Chinese neurosurgical journal 2026; (12(1)).
PMID: 42260690 - 8
Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section.
Ng S, Messerer M, Engelhardt J, et al.
Acta neurochirurgica 2021; (163(11)):3131-3142 doi:10.1007/s00701-021-04953-6.
PMID: 34365544 - 9
Metastatic pituitary tumors: an institutional case series.
Yearley AG, Chalif EJ, Gupta S, et al.
Pituitary 2023; (26(5)):561-572 doi:10.1007/s11102-023-01341-4.
PMID: 37523025 - 10
How to standardize the diagnostic approach to pituitary neuroendocrine tumors.
Asioli S, Guaraldi F, Zoli M, et al.
Minerva endocrinology 2024; (49(3)):283-292 doi:10.23736/S2724-6507.24.04079-X.
PMID: 38656092 - 11
Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification.
Ho KKY, Kaiser UB, Chanson P, et al.
Nature reviews. Endocrinology 2023; (19(11)):671-678 doi:10.1038/s41574-023-00883-8.
PMID: 37592077 - 12
How often should we perform magnetic resonance imaging (MRI) for the follow-up of pituitary adenoma?
Constantinescu SM, Duprez T, Bonneville JF, Maiter D
Annales d'endocrinologie 2024; (85(4)):300-307 doi:10.1016/j.ando.2024.03.004.
PMID: 38604408 - 13
Double pituitary adenomas in a large surgical series.
Zieliński G, Sajjad EA, Maksymowicz M, et al.
Pituitary 2019; (22(6)):620-632 doi:10.1007/s11102-019-00996-2.
PMID: 31598814 - 14
Aggressive and Metastatic Pituitary Neuroendocrine Tumors: Therapeutic Management and Off-Label Drug Use.
Iglesias P
Journal of clinical medicine 2023; (13(1)) doi:10.3390/jcm13010116.
PMID: 38202123 - 15
Success of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor.
Wolf KI, Lu Z, Hesseltine EA, et al.
Endocrine oncology (Bristol, England) 2025; (5(1)):e250073 doi:10.1530/EO-25-0073.
PMID: 41126982
This page is for informational purposes only and does not constitute medical advice. Your pituitary care team should review your records and guide decisions about testing and treatment for your individual situation.
Get notified when new evidence is published on Pituitary carcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.